Prostate Cancer
Conditions
Keywords
adenocarcinoma of the prostate, stage IIB prostate cancer, stage IIA prostate cancer, stage III prostate cancer
Brief summary
RATIONALE: Hormones can stimulate the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which regimen of hormone therapy and radiation therapy is more effective for prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of two different regimens of hormone therapy and radiation therapy in treating patients who have prostate cancer.
Detailed description
OBJECTIVES: * Compare the efficacy of moderate-duration (28 weeks) neoadjuvant total androgen suppression (TAS) and radiotherapy (RT) with short-duration (8 weeks) neoadjuvant TAS and RT, as related to disease-specific survival, in patients with intermediate-risk adenocarcinoma of the prostate. * Compare these regimens, in terms of overall survival, disease-free survival, time to local tumor progression or distant failure, time to first biochemical failure, hormone-refractory state, and treatment-induced morbidity, in this patient population. OUTLINE: This is a randomized, multicenter study. Patients are stratified according to prostate-specific antigen level (no greater than 10 ng/mL vs greater than 10 but no greater than 20 ng/mL vs greater than 20 ng/mL), tumor stage (T1b-2 vs T3-4), Gleason score (2-4 vs 5-6 vs 7-10), and prior hormonal therapy (yes vs no). Patients are randomized to one of two treatment arms. * Arm I: Patients receive total androgen suppression for 8 weeks prior to the initiation of radiotherapy and throughout radiotherapy. A luteinizing hormone-releasing hormone (LHRH) agonist is administered every 1-3 months AND bicalutamide OR flutamide is given orally daily for a total duration of 16 weeks. Beginning with week 9, patients undergo radiotherapy 5 days a week for 8 weeks. * Arm II: Patients receive total androgen suppression for 28 weeks prior to the initiation of radiotherapy and throughout radiotherapy. An LHRH agonist AND bicalutamide OR flutamide are administered as in arm I for a total duration of 36 weeks. Beginning with week 29, patients undergo radiotherapy as in arm I. Patients are followed every 3 months for 1 year, every 6 months for 4 years, and then annually thereafter. PROJECTED ACCRUAL: A total of 1,540 patients (770 per treatment arm) will be accrued for this study within 4 years.
Interventions
DRUGCasodex
Orally at a dose of one 50 mg tablet per day started within (before or after) 14 days of the first LHRH agonist injection.
DRUGEulexin
Orally at a dose of two 125 mg capsules three times a day for a total daily dose of 750 mg (six capsules) started within (before or after) 14 days of the first LHRH agonist injection.
DRUGLHRH agonist
LHRH agonist of choice. The manufacturer's instructions should be followed.
RADIATIONradiation therapy
\[Prostate and any extraprostatic tumor extension + 1.0-1.5 cm margin receives 70.2 Gy (1.8 Gy/day x 39 fractions, five days/week)\] OR \[regional nodes, prostate and seminal vesicles + 1.0-1.5 cm margin will receive 46.8 Gy (1.8 Gy/day x 26 fractions, five days/week), followed by a 23.4 Gy (1.8 Gy/day x 13 fractions, five days/week) boost to the prostate and any extraprostatic tumor extension + 1.0-1.5 cm margin\]
Sponsors
National Cancer Institute (NCI)
Radiation Therapy Oncology Group
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 120 Years
Healthy volunteers
No
Inclusion criteria
1. Adenocarcinoma of prostatic origin histologically-confirmed within 180 days of the randomization date. 2. Zubrod Performance Status 0-1 (Appendix II). 3. Prostatic biopsy tumor grading by the Gleason Score classification (Appendix VI) is mandatory prior to randomization. 4. Patients at intermediate risk for disease relapse as determined by any of the following combinations of factors (NOTE: tumor found in one or both lobes on biopsy, but not palpable, will not alter T stage): * Clinical stage T1b-4, Gleason score 2-6, and prostate-specific antigen \>10 but ≤ 100. * Clinical stage T1b-4, Gleason score 7, and prostate-specific antigen \< 20. * Clinical stage T1b-1c, Gleason score 8-10, and prostate-specific antigen \<20. 5. Clinically negative (N0) lymph nodes (LN) as established by imaging (pelvic ± abdominal CT, MRI or LAG), or negative LN by nodal sampling or dissection (laparoscopy or laparotomy). Patients with radiologic (e.g., CT, MRI or LAG) or radioimmunoscintigraphy (i.e., ProstaScint™) findings suggestive of regional nodal involvement are eligible if cytologic (e.g., needle aspiration) or histologic (e.g., surgical sampling) evaluation shows no evidence of a neoplastic process (i.e., prostatic or non-prostatic malignancy). Patients with equivocal radiologic findings (maximum nodal size ≤ 1.5 cm) are eligible. 6. No distant (M0) metastases. Patients with radionuclide imaging (e.g., bone scintigraphy, ProstaScint™) findings suggestive, but not diagnostic of metastatic disease are eligible if radiologic (e.g., standard or tomographic radiography, or CT/MRI) imaging does not confirm metastatic disease. 7. Pretherapy serum (total) prostate-specific antigen value performed with a Federal Drug Administration approved assay method, e.g. Abbott, Hybritech, etc. 8. Treatment must begin within 6 weeks after randomization. 9. Alanine aminotransferase (ALT) must be within 2 x upper normal limit. 10. Patients must sign a study-specific informed consent form (Appendix I) prior to randomization.
Exclusion criteria
1. Patients at high risk for disease relapse as determined by either: * Prostate-specific antigen ≥ 20 and Gleason score ≥ 7 (any T stage). * Clinical stage ≥T2 and Gleason score ≥ 8 (any prostate-specific antigen). 2. Patients at low risk for disease relapse as determined by: • Clinical stage ≤T2, Gleason score ≤ 6, and prostate-specific antigen ≤ 10. 3. Clinical stage Tx, T0, or T1a. 4. Histologic or radiologic evidence of tumor involvement of regional lymph nodes (N1) or the presence of metastatic disease (M1). 5. Pretherapy serum prostate-specific antigen level \> 100. 6. Co-morbid medical illness which in the opinion of the investigator is expected to result in a life expectancy of \<10 years. 7. Any of the following prior therapies: * Pelvic external beam radiation therapy. * Radionuclide prostate brachytherapy. * Prostatectomy or prostatic cryosurgery. * Prior bilateral orchiectomy. * Prior androgen suppression therapy; however, patients begun on LHRH agonist therapy remain eligible if (1) LHRH agonists were started no more than 30 days before randomization, and (2) Casodex or Eulexin was (or will be) started no more than 14 days before or after the date that the LHRH agonist injection was given. Any finasteride therapy administered for prostatic hypertrophy must be discontinued. * Chemotherapy for prostatic carcinoma. 8. Previous or concomitant invasive cancer, other than localized basal cell or squamous cell skin carcinoma (AJCC Stage 0-II), unless continually disease free for at least 5 years. 9. Major medical or psychiatric illness which, in the opinion of the investigator, would prevent completion of treatment or would interfere with follow-up. 10. The patient's participation in another medical research study that involves prostate cancer treatment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Disease-specific Survival (DSS) (10-year Rates Reported) | From randomization to 10 years. (Patients are followed until death or study termination, whichever occurs first.) | Disease-specific survival time is measured from date of randomization to death due to prostate cancer based on study chair review, with prostate-cancer death defined as (1) primary cause of death certified as due to prostate cancer, (2) complication of therapy, irrespective of disease status, (3) disease progression in the absence of any anti-tumor therapy, or (4) a 1.0 ng/ml-exceeding-rise in serum prostate-specific antigen (PSA) level on at least two consecutive occasions that occurs during or after salvage androgen suppression therapy. Death due to other causes is considered a competing risk. All others are censored. DSS is estimated using the cumulative incidence method. Ten-year rate is reported. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease-free Survival (DFS) (10-year Rates Reported) | From randomization to 10 years. (Patients are followed until death or study termination, whichever occurs first.) | Disease-free survival time is defined as time from randomization to the date of disease progression or death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. Ten-year rate is reported. |
| Clinical Patterns of Tumor Recurrence: Time to Locoregional Progression (LRP) and Time to Distant Metastasis (DM) (10 Year Rates Reported) | From randomization to 10 years. (Patients are followed until death or study termination, whichever occurs first.) | Time to distant metastasis measured from date of randomization to date of documented distant metastasis; competing risks are BF, LRP, and death without DM; all others are censored. Time to locoregional progression measured from date of randomization to date of documented local or regional progression; competing risks are BF \[protocol definition- first of (1) the midway date between the last non-rising PSA and the first rising PSA of three consecutive rises or (2) the date of the initiation of salvage hormone therapy\], DM, and death without LRP; all others are censored. LRP and DM are estimated using the cumulative incidence method. Ten -year rates are reported. |
| Overall Survival (OS) (10-year Rates Reported) | From randomization to 10 years. (Patients are followed until death or study termination, whichever occurs first.) | Survival time is defined as time from randomization to the date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. Ten-year rate is reported. |
| Time to Second Biochemical Failure (SBF) (10-year Rates Reported) | From randomization to 10 years. (Patients are followed until death or study termination, whichever occurs first.) | Time to SBF measured from date of randomization to the date of PSA increase of ≥1.0 ng/mL (from the nadir PSA after completion of protocol-specified therapy) after salvage androgen suppression was started; competing risks LRP, DM, and death without SBF; all others are censored. SBF is estimated using the cumulative incidence method. Ten-year rates are reported. |
| Treatment-induced Morbidity (Highest Grade Toxicity Reported Per Patient) | From randomization to 10 years. (Patients are followed until death or study termination, whichever occurs first.) | Acute drug therapy and radiation (\<= 90 days from start of RT) toxicity was graded using the Common Toxicity Criteria (CTC) v.2.0 criteria; late toxicity was graded using the Radiation Therapy Oncology Group (RTOG)/European Organisation for Research and Treatment of Cancer (EORTC) Late Radiation Morbidity Scoring schema. Grade refers to the severity of the toxicity. The CTC v2.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each toxicity based on this general guideline: Grade 1 Mild toxicity, Grade 2 Moderate toxicity, Grade 3 Severe toxicity, Grade 4 Life-threatening or disabling toxicity, Grade 5 Death related to toxicity. The highest grade acute and late toxicity was determined for each patient. |
| Time to First Biochemical Failure (BF) (10-year Rates Reported) | From randomization to 10 years. (Patients are followed until death or study termination, whichever occurs first.) | Protocol definition: Time to BF measured from date of randomization to first of (1) the midway date between the last non-rising PSA and the first rising PSA of three consecutive rises or (2) the date of the initiation of salvage hormone therapy; competing risks are LRP, DM, and death without BF; all others are censored. Phoenix definition: Time to BF measured from date of randomization to first of (1) the date of documented rise of 2 ng/ml above the post-treatment(RT end date) nadir or (2) the date of the initiation of salvage hormone therapy; competing risks are LRP, DM, and death without BF; all others are censored. For both definitions BF is estimated using the cumulative incidence method. Ten year rates reported. |
Countries
Canada, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| TAS x 8 Weeks Total Androgen Suppression (TAS) (LHRH agonist and Casodex or Eulexin) x 8 weeks followed by radiation therapy (RT) with concurrent TAS (LHRH agonist and Casodex or Eulexin). | 752 |
| TAS x 28 Weeks TAS (LHRH agonist and Casodex or Eulexin) x 28 weeks followed by RT with concurrent TAS (LHRH agonist and Casodex or Eulexin). | 737 |
| Total | 1,489 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | No protocol treatment | 0 | 1 |
| Overall Study | Protocol Violation | 37 | 46 |
| Overall Study | Withdrawal by Subject | 1 | 5 |
Baseline characteristics
| Characteristic | TAS x 8 Weeks | TAS x 28 Weeks | Total |
|---|---|---|---|
| Age, Continuous | 71 years | 71 years | 71 years |
| Sex: Female, Male Female | 0 Participants | 0 Participants | 0 Participants |
| Sex: Female, Male Male | 752 Participants | 737 Participants | 1489 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 695 / 747 | 707 / 735 |
| serious Total, serious adverse events | 121 / 747 | 109 / 735 |
Outcome results
Primary
Disease-specific Survival (DSS) (10-year Rates Reported)
Disease-specific survival time is measured from date of randomization to death due to prostate cancer based on study chair review, with prostate-cancer death defined as (1) primary cause of death certified as due to prostate cancer, (2) complication of therapy, irrespective of disease status, (3) disease progression in the absence of any anti-tumor therapy, or (4) a 1.0 ng/ml-exceeding-rise in serum prostate-specific antigen (PSA) level on at least two consecutive occasions that occurs during or after salvage androgen suppression therapy. Death due to other causes is considered a competing risk. All others are censored. DSS is estimated using the cumulative incidence method. Ten-year rate is reported.
Time frame: From randomization to 10 years. (Patients are followed until death or study termination, whichever occurs first.)
Population: Eligible patients with follow-up data
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| TAS x 8 Weeks | Disease-specific Survival (DSS) (10-year Rates Reported) | 95 percentage of participants |
| TAS x 28 Weeks | Disease-specific Survival (DSS) (10-year Rates Reported) | 96 percentage of participants |
Comparison: Assuming 40% of deaths in the 8-wk arm from prostate cancer (PC) and that 8-yr DSS would be 79%, 270 PC deaths were required to detect a 33% hazard reduction in the 28-wk arm with 90% power using the log-rank test with a 2-sided significance level of 0.05. Under assumed failure rates, 1,540 patients accrued over 4 years and observed for an additional 6 years were expected to provide the requisite events. This sample accounted for a 10% ineligible/lack-of-data rate and 3 interim analyses.p-value: 0.4595% CI: [0.48, 1.39]Log Rank
Secondary
Clinical Patterns of Tumor Recurrence: Time to Locoregional Progression (LRP) and Time to Distant Metastasis (DM) (10 Year Rates Reported)
Time to distant metastasis measured from date of randomization to date of documented distant metastasis; competing risks are BF, LRP, and death without DM; all others are censored. Time to locoregional progression measured from date of randomization to date of documented local or regional progression; competing risks are BF \[protocol definition- first of (1) the midway date between the last non-rising PSA and the first rising PSA of three consecutive rises or (2) the date of the initiation of salvage hormone therapy\], DM, and death without LRP; all others are censored. LRP and DM are estimated using the cumulative incidence method. Ten -year rates are reported.
Time frame: From randomization to 10 years. (Patients are followed until death or study termination, whichever occurs first.)
Population: Eligible patients with follow-up data
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| TAS x 8 Weeks | Clinical Patterns of Tumor Recurrence: Time to Locoregional Progression (LRP) and Time to Distant Metastasis (DM) (10 Year Rates Reported) | Locoregional progression | 6 percentage of participants |
| TAS x 8 Weeks | Clinical Patterns of Tumor Recurrence: Time to Locoregional Progression (LRP) and Time to Distant Metastasis (DM) (10 Year Rates Reported) | Distant metastasis | 6 percentage of participants |
| TAS x 28 Weeks | Clinical Patterns of Tumor Recurrence: Time to Locoregional Progression (LRP) and Time to Distant Metastasis (DM) (10 Year Rates Reported) | Locoregional progression | 4 percentage of participants |
| TAS x 28 Weeks | Clinical Patterns of Tumor Recurrence: Time to Locoregional Progression (LRP) and Time to Distant Metastasis (DM) (10 Year Rates Reported) | Distant metastasis | 6 percentage of participants |
Comparison: Locoregional progressionp-value: 0.0795% CI: [0.4, 1.05]Gray's test
Comparison: Distant metastasisp-value: 0.895% CI: [0.68, 1.66]Gray's test
Secondary
Disease-free Survival (DFS) (10-year Rates Reported)
Disease-free survival time is defined as time from randomization to the date of disease progression or death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. Ten-year rate is reported.
Time frame: From randomization to 10 years. (Patients are followed until death or study termination, whichever occurs first.)
Population: Eligible patients without follow-up data
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| TAS x 8 Weeks | Disease-free Survival (DFS) (10-year Rates Reported) | 24 percentage of participants |
| TAS x 28 Weeks | Disease-free Survival (DFS) (10-year Rates Reported) | 23 percentage of participants |
p-value: 0.4795% CI: [0.85, 1.08]Log Rank
Secondary
Overall Survival (OS) (10-year Rates Reported)
Survival time is defined as time from randomization to the date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. Ten-year rate is reported.
Time frame: From randomization to 10 years. (Patients are followed until death or study termination, whichever occurs first.)
Population: Eligible patients with follow-up data
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| TAS x 8 Weeks | Overall Survival (OS) (10-year Rates Reported) | 66 percentage of participants |
| TAS x 28 Weeks | Overall Survival (OS) (10-year Rates Reported) | 67 percentage of participants |
Comparison: With 1540 patients accrued over 4 years and observed for an additional 6 years, determined for the primary endpoint, there would be 90% power to detect a 22% reduction in the hazard of all cause deaths in the 28-week arm, with 2-sided significance level of 0.05. This sample accounted for a 10% ineligible/lack-of-data rate.p-value: 0.6295% CI: [0.79, 1.15]Log Rank
Secondary
Time to First Biochemical Failure (BF) (10-year Rates Reported)
Protocol definition: Time to BF measured from date of randomization to first of (1) the midway date between the last non-rising PSA and the first rising PSA of three consecutive rises or (2) the date of the initiation of salvage hormone therapy; competing risks are LRP, DM, and death without BF; all others are censored. Phoenix definition: Time to BF measured from date of randomization to first of (1) the date of documented rise of 2 ng/ml above the post-treatment(RT end date) nadir or (2) the date of the initiation of salvage hormone therapy; competing risks are LRP, DM, and death without BF; all others are censored. For both definitions BF is estimated using the cumulative incidence method. Ten year rates reported.
Time frame: From randomization to 10 years. (Patients are followed until death or study termination, whichever occurs first.)
Population: Eligible patients with follow-up data
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| TAS x 8 Weeks | Time to First Biochemical Failure (BF) (10-year Rates Reported) | Protocol definition | 56 percentage of participants |
| TAS x 8 Weeks | Time to First Biochemical Failure (BF) (10-year Rates Reported) | Phoenix definition | 27 percentage of participants |
| TAS x 28 Weeks | Time to First Biochemical Failure (BF) (10-year Rates Reported) | Protocol definition | 59 percentage of participants |
| TAS x 28 Weeks | Time to First Biochemical Failure (BF) (10-year Rates Reported) | Phoenix definition | 27 percentage of participants |
Comparison: Protocol definitionp-value: 0.7495% CI: [0.89, 1.17]Gray's test
Comparison: Phoenix definitionp-value: 0.7795% CI: [0.79, 1.19]Gray's test
Secondary
Time to Second Biochemical Failure (SBF) (10-year Rates Reported)
Time to SBF measured from date of randomization to the date of PSA increase of ≥1.0 ng/mL (from the nadir PSA after completion of protocol-specified therapy) after salvage androgen suppression was started; competing risks LRP, DM, and death without SBF; all others are censored. SBF is estimated using the cumulative incidence method. Ten-year rates are reported.
Time frame: From randomization to 10 years. (Patients are followed until death or study termination, whichever occurs first.)
Population: Eligible patients with follow-up data
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| TAS x 8 Weeks | Time to Second Biochemical Failure (SBF) (10-year Rates Reported) | 10 percentage of participants |
| TAS x 28 Weeks | Time to Second Biochemical Failure (SBF) (10-year Rates Reported) | 9 percentage of participants |
p-value: 0.6295% CI: [0.64, 1.3]Log Rank
Secondary
Treatment-induced Morbidity (Highest Grade Toxicity Reported Per Patient)
Acute drug therapy and radiation (\<= 90 days from start of RT) toxicity was graded using the Common Toxicity Criteria (CTC) v.2.0 criteria; late toxicity was graded using the Radiation Therapy Oncology Group (RTOG)/European Organisation for Research and Treatment of Cancer (EORTC) Late Radiation Morbidity Scoring schema. Grade refers to the severity of the toxicity. The CTC v2.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each toxicity based on this general guideline: Grade 1 Mild toxicity, Grade 2 Moderate toxicity, Grade 3 Severe toxicity, Grade 4 Life-threatening or disabling toxicity, Grade 5 Death related to toxicity. The highest grade acute and late toxicity was determined for each patient.
Time frame: From randomization to 10 years. (Patients are followed until death or study termination, whichever occurs first.)
Population: Eligible patients with adverse event data in corresponding time frame (during hormone therapy and \<=90 days from RT start; \> 90 days from RT start)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| TAS x 8 Weeks | Treatment-induced Morbidity (Highest Grade Toxicity Reported Per Patient) | Acute RT and Hormone Toxicity: Grade 1 | 30.8 percentage of participants |
| TAS x 8 Weeks | Treatment-induced Morbidity (Highest Grade Toxicity Reported Per Patient) | Acute RT and Hormone Toxicity: Grade 2 | 41.6 percentage of participants |
| TAS x 8 Weeks | Treatment-induced Morbidity (Highest Grade Toxicity Reported Per Patient) | Acute RT and Hormone Toxicity: Grade 3 | 16.1 percentage of participants |
| TAS x 8 Weeks | Treatment-induced Morbidity (Highest Grade Toxicity Reported Per Patient) | Acute RT and Hormone Toxicity: Grade 4 | 0 percentage of participants |
| TAS x 8 Weeks | Treatment-induced Morbidity (Highest Grade Toxicity Reported Per Patient) | Acute RT and Hormone Toxicity: Grade 5 | 0 percentage of participants |
| TAS x 8 Weeks | Treatment-induced Morbidity (Highest Grade Toxicity Reported Per Patient) | Late RT Toxicity: Grade 1 | 34.0 percentage of participants |
| TAS x 8 Weeks | Treatment-induced Morbidity (Highest Grade Toxicity Reported Per Patient) | Late RT Toxicity: Grade 2 | 20.5 percentage of participants |
| TAS x 8 Weeks | Treatment-induced Morbidity (Highest Grade Toxicity Reported Per Patient) | Late RT Toxicity: Grade 3 | 9.7 percentage of participants |
| TAS x 8 Weeks | Treatment-induced Morbidity (Highest Grade Toxicity Reported Per Patient) | Late RT Toxicity: Grade 4 | 0.1 percentage of participants |
| TAS x 8 Weeks | Treatment-induced Morbidity (Highest Grade Toxicity Reported Per Patient) | Late RT Toxicity: Grade 5 | 0 percentage of participants |
| TAS x 28 Weeks | Treatment-induced Morbidity (Highest Grade Toxicity Reported Per Patient) | Late RT Toxicity: Grade 3 | 8.0 percentage of participants |
| TAS x 28 Weeks | Treatment-induced Morbidity (Highest Grade Toxicity Reported Per Patient) | Acute RT and Hormone Toxicity: Grade 1 | 19.5 percentage of participants |
| TAS x 28 Weeks | Treatment-induced Morbidity (Highest Grade Toxicity Reported Per Patient) | Late RT Toxicity: Grade 1 | 32.9 percentage of participants |
| TAS x 28 Weeks | Treatment-induced Morbidity (Highest Grade Toxicity Reported Per Patient) | Acute RT and Hormone Toxicity: Grade 2 | 49.8 percentage of participants |
| TAS x 28 Weeks | Treatment-induced Morbidity (Highest Grade Toxicity Reported Per Patient) | Late RT Toxicity: Grade 5 | 0 percentage of participants |
| TAS x 28 Weeks | Treatment-induced Morbidity (Highest Grade Toxicity Reported Per Patient) | Acute RT and Hormone Toxicity: Grade 3 | 25.7 percentage of participants |
| TAS x 28 Weeks | Treatment-induced Morbidity (Highest Grade Toxicity Reported Per Patient) | Late RT Toxicity: Grade 2 | 22.5 percentage of participants |
| TAS x 28 Weeks | Treatment-induced Morbidity (Highest Grade Toxicity Reported Per Patient) | Acute RT and Hormone Toxicity: Grade 4 | 0.1 percentage of participants |
| TAS x 28 Weeks | Treatment-induced Morbidity (Highest Grade Toxicity Reported Per Patient) | Late RT Toxicity: Grade 4 | 0.3 percentage of participants |
| TAS x 28 Weeks | Treatment-induced Morbidity (Highest Grade Toxicity Reported Per Patient) | Acute RT and Hormone Toxicity: Grade 5 | 0 percentage of participants |